CRISPR Therapeutics AG
Why CSRP Stock Is a Good Buy Despite Losses
The Best Gene-Editing ETF for Your Portfolio in 2021
Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday
On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.
A Financial Overview of Sangamo Therapeutics in December 2018
In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.
Taking Stock of Vertex’s Performance
Vertex Pharmaceuticals (VRTX) focuses on developing cystic fibrosis therapies and bringing them to market.
Editas Stock: Analysts’ Recommendations
In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”
CRISPR Therapeutics: Analysts’ View in November
On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.
How Is Vertex Pharmaceuticals Positioned in October?
Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.
Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space
Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter.
A Financial Overview of Intellia Therapeutics in September
In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million.
Analysts Are Mostly Positive on Intellia Therapeutics This Month
On September 10, Intellia Therapeutics stock closed at $26.98, a ~0.95% fall from the previous day’s close of $27.24.
How CRISPR Therapeutics Is Positioned in September
CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.
How Analysts Rate Editas Medicine and Peers in August
Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.
CRISPR, Intellia, and Caribou Receive a US Genome-Editing Patent
On June 19, the co-owners of intellectual property associated with CRISPR-Cas9 genome editing technology were granted a US patent.
Why Editas Medicine Fell 7.8% on Monday
On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.
Crispr Therapeutics Stock Fell 12.6% on June 11
On June 11, Crispr Therapeutics (CRSP) stock fell 12.6% to $59.57 over concerns that the CRISPR-CAS9 Gene Therapy causes cancer.
CRISPR Stock Has Seen Soild Growth in the Last 12 Months
CRISPR Therapeutics has risen 24% between May 11 and May 17.